- Home
- DAWN vs INAB Comparison
DAWN vs INAB Comparison
Compare DAWN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- INAB
- Stock Information
- Founded
- DAWN 2018
- INAB 2016
- Country
- DAWN United States
- INAB United States
- Employees
- DAWN N/A
- INAB N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- INAB Health Care
- Exchange
- DAWN Nasdaq
- INAB Nasdaq
- Market Cap
- DAWN 1.3B
- INAB 24.0M
- IPO Year
- DAWN 2021
- INAB 2021
- Fundamental
- Price
- DAWN $12.79
- INAB $0.25
- Analyst Decision
- DAWN Strong Buy
- INAB Strong Buy
- Analyst Count
- DAWN 7
- INAB 3
- Target Price
- DAWN $36.17
- INAB $7.75
- AVG Volume (30 Days)
- DAWN 937.9K
- INAB 727.4K
- Earning Date
- DAWN 10-30-2024
- INAB 11-12-2024
- Dividend Yield
- DAWN N/A
- INAB N/A
- EPS Growth
- DAWN N/A
- INAB N/A
- EPS
- DAWN N/A
- INAB N/A
- Revenue
- DAWN $101,953,000.00
- INAB N/A
- Revenue This Year
- DAWN N/A
- INAB N/A
- Revenue Next Year
- DAWN $36.10
- INAB N/A
- P/E Ratio
- DAWN N/A
- INAB N/A
- Revenue Growth
- DAWN N/A
- INAB N/A
- 52 Week Low
- DAWN $11.94
- INAB $0.22
- 52 Week High
- DAWN $18.07
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- INAB 39.26
- Support Level
- DAWN $12.26
- INAB $0.28
- Resistance Level
- DAWN $12.81
- INAB $0.32
- Average True Range (ATR)
- DAWN 0.52
- INAB 0.03
- MACD
- DAWN -0.05
- INAB -0.01
- Stochastic Oscillator
- DAWN 28.94
- INAB 13.73
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.